Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion
Novartis will pay $575 million upfront for worldwide rights to Abogen's mRNA T-cell engager, plus up to $7.2 billion in milestones.
/ 24 items
#NVS↓
Roche and Ionis Report Phase 3 Proteinuria Win for Sefaxersen in IgA Nephropathy
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
BoomRay Signs Exclusive $900 Million Radioligand Deal With Novartis
Chinese biotech BoomRay licenses a preclinical radioligand therapy to Novartis in a deal worth up to $900 million plus royalties.
Amgen Drug Succeeds in Late-Stage Sjögren’s Disease Trial
Amgen’s dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026.
FDA Approves First SMA Drug That Targets Muscle Loss, Not Just Nerves
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
Major Novartis Shareholder Calls for Board Shake-Up After Two Failed Drug Trials
Artisan Partners wants Novartis board changes after Avidity’s del-desiran and pelacarsen failed late-stage trials and wiped out $30B in value.